Concepts (159)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fat Emulsions, Intravenous | 24 | 2023 | 37 | 6.080 |
Why?
|
| Parenteral Nutrition, Total | 16 | 2013 | 27 | 3.800 |
Why?
|
| Fatty Acids, Omega-3 | 6 | 2024 | 36 | 3.040 |
Why?
|
| Parenteral Nutrition | 12 | 2023 | 21 | 2.930 |
Why?
|
| Drug Stability | 20 | 2024 | 141 | 2.010 |
Why?
|
| Phosphates | 6 | 2012 | 90 | 1.790 |
Why?
|
| Nanoparticles | 3 | 2024 | 493 | 1.690 |
Why?
|
| Triglycerides | 11 | 2024 | 231 | 1.670 |
Why?
|
| Fish Oils | 5 | 2023 | 42 | 1.660 |
Why?
|
| Particle Size | 18 | 2024 | 395 | 1.620 |
Why?
|
| Plastics | 7 | 2009 | 19 | 1.580 |
Why?
|
| Amino Acids | 5 | 2012 | 140 | 1.120 |
Why?
|
| Soybean Oil | 5 | 2023 | 31 | 1.070 |
Why?
|
| Emulsions | 5 | 2024 | 457 | 0.980 |
Why?
|
| Parenteral Nutrition Solutions | 3 | 2014 | 4 | 0.970 |
Why?
|
| Drug Packaging | 7 | 2009 | 11 | 0.950 |
Why?
|
| Glass | 4 | 2007 | 21 | 0.910 |
Why?
|
| Phytosterols | 1 | 2023 | 8 | 0.850 |
Why?
|
| Liver Failure | 1 | 2023 | 17 | 0.850 |
Why?
|
| Lipids | 2 | 2024 | 300 | 0.820 |
Why?
|
| Intestinal Diseases | 1 | 2023 | 34 | 0.820 |
Why?
|
| Liver | 5 | 2015 | 797 | 0.770 |
Why?
|
| Liver Diseases | 1 | 2023 | 138 | 0.760 |
Why?
|
| Infant Nutritional Physiological Phenomena | 2 | 2014 | 15 | 0.760 |
Why?
|
| Calcium | 3 | 2009 | 555 | 0.690 |
Why?
|
| Food, Formulated | 2 | 2010 | 10 | 0.680 |
Why?
|
| Aluminum | 2 | 2012 | 14 | 0.640 |
Why?
|
| Olive Oil | 2 | 2017 | 7 | 0.620 |
Why?
|
| Potassium Compounds | 2 | 2008 | 6 | 0.600 |
Why?
|
| Glucose | 2 | 2012 | 445 | 0.600 |
Why?
|
| Drug Compounding | 4 | 2006 | 75 | 0.570 |
Why?
|
| Oxidative Stress | 3 | 2009 | 279 | 0.550 |
Why?
|
| Analysis of Variance | 8 | 2010 | 589 | 0.540 |
Why?
|
| Humans | 35 | 2024 | 59360 | 0.540 |
Why?
|
| Infant, Newborn | 10 | 2013 | 1283 | 0.460 |
Why?
|
| Guideline Adherence | 2 | 2014 | 290 | 0.450 |
Why?
|
| Drug Storage | 4 | 2009 | 21 | 0.440 |
Why?
|
| Cardiovascular Diseases | 1 | 2021 | 788 | 0.430 |
Why?
|
| Infant, Premature | 3 | 2011 | 175 | 0.410 |
Why?
|
| Liposomes | 2 | 2023 | 100 | 0.410 |
Why?
|
| Infusions, Parenteral | 3 | 2008 | 21 | 0.410 |
Why?
|
| Calcium Chloride | 1 | 2012 | 18 | 0.400 |
Why?
|
| Electrolytes | 1 | 2012 | 25 | 0.400 |
Why?
|
| Hydrogen-Ion Concentration | 6 | 2010 | 450 | 0.380 |
Why?
|
| Pharmacopoeias as Topic | 5 | 2010 | 5 | 0.380 |
Why?
|
| Calcium Gluconate | 2 | 2009 | 5 | 0.380 |
Why?
|
| Chemical Phenomena | 4 | 2016 | 94 | 0.370 |
Why?
|
| Lung | 2 | 2006 | 919 | 0.350 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2024 | 35 | 0.330 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2006 | 56 | 0.330 |
Why?
|
| Solutions | 2 | 2008 | 64 | 0.330 |
Why?
|
| Calcium Phosphates | 1 | 2008 | 7 | 0.310 |
Why?
|
| Osmolar Concentration | 4 | 2009 | 88 | 0.310 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2009 | 41 | 0.310 |
Why?
|
| Chemical Precipitation | 4 | 2009 | 11 | 0.300 |
Why?
|
| Hypertriglyceridemia | 1 | 2007 | 8 | 0.290 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2008 | 75 | 0.280 |
Why?
|
| Time Factors | 7 | 2010 | 3617 | 0.280 |
Why?
|
| Nutritional Support | 2 | 2004 | 12 | 0.280 |
Why?
|
| Pharmaceutical Preparations | 2 | 2005 | 117 | 0.270 |
Why?
|
| Dietary Fats, Unsaturated | 2 | 2017 | 19 | 0.270 |
Why?
|
| Mononuclear Phagocyte System | 1 | 2006 | 3 | 0.260 |
Why?
|
| Infusions, Intravenous | 3 | 2014 | 164 | 0.260 |
Why?
|
| Food | 1 | 2006 | 76 | 0.260 |
Why?
|
| Plant Oils | 2 | 2016 | 56 | 0.250 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2024 | 14 | 0.230 |
Why?
|
| Catholicism | 1 | 2004 | 4 | 0.230 |
Why?
|
| Anesthetics, Intravenous | 1 | 2004 | 23 | 0.230 |
Why?
|
| Propofol | 1 | 2004 | 21 | 0.230 |
Why?
|
| Fats | 1 | 2004 | 18 | 0.230 |
Why?
|
| Withholding Treatment | 1 | 2004 | 40 | 0.230 |
Why?
|
| Animals | 8 | 2024 | 19651 | 0.220 |
Why?
|
| Fluid Therapy | 1 | 2004 | 47 | 0.220 |
Why?
|
| Temperature | 3 | 2010 | 295 | 0.210 |
Why?
|
| Drug Incompatibility | 3 | 2008 | 3 | 0.210 |
Why?
|
| Fatty Acids | 3 | 2016 | 190 | 0.210 |
Why?
|
| Sterilization | 1 | 2003 | 15 | 0.210 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2009 | 574 | 0.200 |
Why?
|
| Random Allocation | 3 | 2009 | 192 | 0.200 |
Why?
|
| Injections | 3 | 2006 | 75 | 0.190 |
Why?
|
| Models, Animal | 3 | 2009 | 221 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 806 | 0.180 |
Why?
|
| Corn Oil | 1 | 2021 | 47 | 0.180 |
Why?
|
| Cell Membrane | 1 | 2023 | 486 | 0.180 |
Why?
|
| Rats | 3 | 2009 | 1910 | 0.170 |
Why?
|
| Intensive Care Units | 1 | 2023 | 423 | 0.160 |
Why?
|
| Aspartate Aminotransferases | 2 | 2009 | 29 | 0.160 |
Why?
|
| Fatty Acids, Essential | 2 | 2015 | 8 | 0.150 |
Why?
|
| Deficiency Diseases | 2 | 2015 | 12 | 0.150 |
Why?
|
| United States | 5 | 2010 | 7390 | 0.150 |
Why?
|
| Malondialdehyde | 2 | 2009 | 13 | 0.150 |
Why?
|
| Chemistry, Physical | 2 | 2006 | 47 | 0.130 |
Why?
|
| Arachidonic Acid | 2 | 2015 | 34 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 164 | 0.120 |
Why?
|
| Safety | 2 | 2006 | 142 | 0.120 |
Why?
|
| Neoplasms | 1 | 2024 | 1240 | 0.110 |
Why?
|
| Lipopolysaccharides | 1 | 2017 | 627 | 0.110 |
Why?
|
| Dietary Fats | 1 | 2013 | 173 | 0.100 |
Why?
|
| Docosahexaenoic Acids | 1 | 2011 | 30 | 0.090 |
Why?
|
| Risk Factors | 1 | 2021 | 4984 | 0.090 |
Why?
|
| Macrophages | 1 | 2017 | 1015 | 0.090 |
Why?
|
| Male | 6 | 2011 | 27739 | 0.090 |
Why?
|
| Inflammation | 1 | 2017 | 1099 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2017 | 2050 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2011 | 170 | 0.080 |
Why?
|
| Reference Values | 1 | 2010 | 326 | 0.080 |
Why?
|
| Catheterization, Peripheral | 1 | 2009 | 46 | 0.080 |
Why?
|
| Glutathione Transferase | 1 | 2009 | 33 | 0.080 |
Why?
|
| Europe | 1 | 2009 | 184 | 0.080 |
Why?
|
| Quality Control | 1 | 2009 | 71 | 0.080 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2008 | 14 | 0.080 |
Why?
|
| Acid-Base Equilibrium | 1 | 2008 | 7 | 0.080 |
Why?
|
| Reference Standards | 1 | 2008 | 71 | 0.080 |
Why?
|
| Lipid Peroxidation | 1 | 2008 | 63 | 0.070 |
Why?
|
| C-Reactive Protein | 1 | 2009 | 159 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2009 | 191 | 0.070 |
Why?
|
| Solubility | 1 | 2008 | 177 | 0.070 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2006 | 6 | 0.070 |
Why?
|
| Micronutrients | 1 | 2006 | 18 | 0.060 |
Why?
|
| Odds Ratio | 1 | 2007 | 745 | 0.060 |
Why?
|
| Pharmaceutical Solutions | 1 | 2005 | 3 | 0.060 |
Why?
|
| Guinea Pigs | 1 | 2005 | 102 | 0.060 |
Why?
|
| Preservatives, Pharmaceutical | 1 | 2004 | 1 | 0.060 |
Why?
|
| Sulfites | 1 | 2004 | 5 | 0.060 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2003 | 20 | 0.050 |
Why?
|
| Mice | 1 | 2017 | 10292 | 0.050 |
Why?
|
| Infant | 1 | 2008 | 1486 | 0.050 |
Why?
|
| Terminal Care | 1 | 2004 | 96 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2003 | 15 | 0.050 |
Why?
|
| Syringes | 1 | 2003 | 10 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2002 | 147 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2004 | 209 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2009 | 3067 | 0.050 |
Why?
|
| Decision Making | 1 | 2004 | 395 | 0.040 |
Why?
|
| Bacteria | 1 | 2003 | 279 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2011 | 6071 | 0.040 |
Why?
|
| Prognosis | 1 | 2004 | 1600 | 0.040 |
Why?
|
| Protective Agents | 1 | 2017 | 9 | 0.030 |
Why?
|
| Oils | 1 | 2017 | 71 | 0.030 |
Why?
|
| Endotoxins | 1 | 2017 | 78 | 0.030 |
Why?
|
| alpha-Linolenic Acid | 1 | 2015 | 4 | 0.030 |
Why?
|
| Linoleic Acid | 1 | 2015 | 18 | 0.030 |
Why?
|
| Oleic Acid | 1 | 2015 | 21 | 0.030 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2015 | 22 | 0.030 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2017 | 339 | 0.030 |
Why?
|
| Water | 1 | 2017 | 300 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2017 | 460 | 0.030 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 588 | 0.030 |
Why?
|
| Adult | 2 | 2013 | 15669 | 0.030 |
Why?
|
| Retinopathy of Prematurity | 1 | 2011 | 10 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2011 | 57 | 0.020 |
Why?
|
| Female | 2 | 2011 | 30705 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 674 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2013 | 705 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 716 | 0.020 |
Why?
|
| Sepsis | 1 | 2011 | 272 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 2902 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2011 | 2374 | 0.020 |
Why?
|
| Child | 1 | 2013 | 4174 | 0.010 |
Why?
|